Pfizer (PFE) Other Gross PP&E Adjustments (2009 - 2025)
Pfizer (PFE) reported Other Gross PP&E Adjustments of $34.5 billion for Q4 2025, up 5.84% year-over-year from $32.6 billion in Q4 2024, and up 5.84% on a QoQ basis from $32.6 billion in Q4 2024.
Pfizer (PFE) has 17 years of Other Gross PP&E Adjustments data on file, last reported at $34.5 billion in Q4 2025.
- Quarterly Other Gross PP&E Adjustments rose 5.84% year-over-year to $34.5 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $34.5 billion (up 5.84% YoY) and the FY2025 annual result came in at $34.5 billion, up 5.84% from the prior year.
- Other Gross PP&E Adjustments rose to $34.5 billion in Q4 2025 per PFE's latest filing, from $32.6 billion in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $34.5 billion in Q4 2025 and bottomed at $27.1 billion in Q4 2021.
- The 5-year median for Other Gross PP&E Adjustments is $32.1 billion (2023), against an average of $30.9 billion.
- The widest annual swing landed in 2021, when Other Gross PP&E Adjustments rose 0.36%; it then advanced 12.71% in 2023.
- Tracing PFE's Other Gross PP&E Adjustments over 5 years: stood at $27.1 billion in 2021, then advanced by 4.9% to $28.4 billion in 2022, then grew by 12.71% to $32.1 billion in 2023, then advanced by 1.64% to $32.6 billion in 2024, then rose by 5.84% to $34.5 billion in 2025.
- Per Business Quant, the three latest PFE Other Gross PP&E Adjustments figures stand at $34.5 billion (Q4 2025), $32.6 billion (Q4 2024), and $32.1 billion (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 49.60 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | -2.70 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 8.42 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -1.53 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34.49 Bn |
| Dec 31, 2025 | 34.49 Bn |
| Dec 31, 2024 | 32.59 Bn |
| Dec 31, 2024 | 32.59 Bn |
| Dec 31, 2023 | 32.06 Bn |
| Dec 31, 2023 | 32.06 Bn |
| Dec 31, 2022 | 28.45 Bn |
| Dec 31, 2022 | 28.45 Bn |
| Dec 31, 2021 | 27.12 Bn |
| Dec 31, 2021 | 27.12 Bn |
| Dec 31, 2020 | 27.02 Bn |
| Dec 31, 2020 | 27.02 Bn |
| Dec 31, 2019 | 26.67 Bn |
| Dec 31, 2019 | 26.67 Bn |
| Sep 29, 2019 | -1.31 Bn |
| Sep 29, 2019 | -1.31 Bn |
| Jun 30, 2019 | -1.27 Bn |
| Jun 30, 2019 | -1.27 Bn |
| Mar 31, 2019 | -1.28 Bn |
| Mar 31, 2019 | -1.28 Bn |
| Dec 31, 2018 | 29.98 Bn |
| Dec 31, 2018 | 29.98 Bn |
| Dec 31, 2017 | 30.04 Bn |
| Dec 31, 2017 | 30.04 Bn |
| Dec 31, 2016 | 28.13 Bn |
| Dec 31, 2016 | 28.13 Bn |
| Dec 31, 2015 | 27.27 Bn |
| Dec 31, 2015 | 27.27 Bn |
| Dec 31, 2014 | 24.99 Bn |
| Dec 31, 2014 | 24.99 Bn |
| Dec 31, 2013 | 4.47 Bn |
| Dec 31, 2013 | 4.47 Bn |
| Dec 31, 2012 | 10.51 Bn |
| Dec 31, 2012 | 10.51 Bn |
| Dec 31, 2011 | 4.23 Bn |
| Dec 31, 2011 | 4.23 Bn |
| Dec 31, 2010 | 4.64 Bn |
| Dec 31, 2010 | 4.64 Bn |
| Dec 31, 2009 | 4.60 Bn |
| Dec 31, 2009 | 4.60 Bn |